[
    {
        "type": "text",
        "text": "基础研究",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "人CD45基因克隆及其在Hela细胞中的表达",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "李捷，许天昱,吴璐琳,张丽芸，卢晓,左大明,陈政良南方医科大学基础医学院免疫学教研室，广东广州510515摘要：目的克隆人CD45cDNA并导人Hela细胞中表达，建立研究CD45功能的细胞模型。方法采用RT-PCR方法从人外周血单个核细胞中扩增CD45基因PTPRC的cDNA,将其克隆至pMD-18T载体。构建重组真核表达载体PcDNA3.1-3xflag-CD45,经HindI和XhoI双酶切及测序验证。将其转染至Hela细胞，以流式细胞术(FCM)和免疫印迹(WB)分析CD45在Hela细胞中的表达情况，碱性磷酸酶试剂盒检测CD45的活性。结果 分离到长约3900bp的人PTPRCcDNA片段,将其插入pMD-18T载体获得了cDNA克隆。酶切和测序结果证实重组表达载体PcDNA3.1-3xflag-CD45构建成功,FCM和WB分析表明CD45能在Hela细胞中有效表达，且表达的重组CD45蛋白具有生物学活性。结论 成功获得人PTPRCcDNA克隆并在Hela细胞中有效表达，为进一步研究CD45功能奠定了基础。",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "关键词：CD45;基因克隆;真核表达;Hela细胞 ",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "Cloning of human CD45 gene and its expression in Hela cells ",
        "text_level": 1,
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "LI Jie,XU Tianyu,WU lulin,ZHANG Liyun,LU Xiao,ZUO Daming,CHEN Zhengliang Departmentofmmunologyholofsicedicaliencesouthernedicalnioersityuangzhou5in ",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "Abstract: Objective To clone human CD45 gene PTPRC and establish Hela cels overexpressing recombinant human CD45 protein. Methods The intact cDNA encoding human CD45 amplified using RT-PCR from the total RNA extracted from peripheral blood mononuclearcels (PBMCs)of a healthy donor was cloned into pMD-18T vector. The CD45cDNA fragment amplified fromthepMD-18T-CD45byPCR was insertedtothecodingregionofthePDNA3.1-3xflag vector,andtheresultant recombinantexpression vectorPcDNA3.1-3xflag-CD45was transfected intoHelacels.The expressonof CD45 inHelacells wasdetectedbyflowcytometryand Westernbloting,andthe phosphastase activityofCD45 wasquantifiedusing analkaline phosphatase assy kit.Results ThecDNA fragment of about 390bp was amplified from human PBMCs and cloned into pMD-18T vector.The recombinant expression vector PcDNA3.1-3xflag-CD45 was constructed, whose restriction maps and sequence wereconsistent with those expected.The expression of CD45 in transfected Helacels was detected by flow cytometryand Westernbloting,and the expressed recombinant CD45 protein inHelacelshowedaphosphastaseactivity. Conclusion ThecDNAofhuman CD45wassuccessfullyclonedandefectivelyexpressed inHelacels,which providesabasis for further exploration of the functions of CD45. ",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "Key words: CD45; gene cloning; eukaryotic expression; Hela cells ",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "蛋白质酪氨酸残基的磷酸化水平为一动态可逆过程。蛋白酪氨酸激酶(PTK)与蛋白酪氨酸磷酸酶(PTP)两大家族构成一个调控网络,精细地调节着酪氨酸残基的磷酸化程度。CD45是白细胞表面共同抗原，表达在除红细胞和血小板之外的所有血液细胞上，在免疫细胞如T细胞、B细胞、自然杀伤细胞和巨噬细胞表面均有表达。该分子为单链跨膜糖蛋白，是PTP家族成员，能特异地水解蛋白质底物上的酪氨酸磷酸酯键以脱去磷酸，与PTK相互配合，调节蛋白质的功能，在免疫细胞的发育和活化中起着重要作用[1]。CD45由4\\~6个外显子(常见的有A、B、C等)交替剪接而成，使其至少有9个变构体即亚型，如CD45RA、CD45RB、CD45RC、CD45RO等。单个细胞可同时表达CD45的多个亚型，虽然这些亚型的胞外段结构不同，但胞浆段具有共同的酪氨酸磷酸酶活性结构域。研究表明，CD45在免疫细胞的信号转导调控中发挥了重要作用2。早在10余年前，我国就开始了对制备放射性元素标记的CD45抗体的研究,为靶向治疗白血病奠定了基础。近年来，越来越多的研究集中在CD45对白血病、淋巴瘤和非造血系统肿瘤的鉴别、诊断和治疗[47。本研究克隆了人CD45基因PTPRC的cDNA,构建重组真核表达载体PcDNA3.1-3xflag-CD45,转染Hela细胞并成功表达，建立了研究CD45功能的细胞模型，为进一步探索CD45的功能奠定了基础。",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 0
    },
    {
        "type": "text",
        "text": "1材料与方法",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1.1质粒菌株和Hela细胞 ",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "Hela 细胞、感受态细菌Top10、pMD-18T载体和PcDNA3.1-3xflag质粒均为本实验室保存。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1.2主要试剂",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "高保真DNA多聚酶购于诺唯赞生物科技有限公司；限制性内切酶HindⅢ和XhoI以及T连接酶购于Takara公司；质粒抽提试剂盒购于美基生物公司；转染试剂PEI购于Sigama公司；DMEM培养基购于Life公司；胎牛血清购于百旺生物公司；PE-CD45抗体为美天旎公司产品;抗标签蛋白单抗购于CST公司;HRP-抗鼠抗体购于杭州联科生物公司；碱性磷酸酶试剂盒购于南京建成生物工程研究所。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1.3培养Hela细胞 ",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "Hela细胞常规培养于含 $10 \\%$ 胎牛血清的DMEM高糖完全培养基中，置于 $3 7 \\ \\%$ （204号 $\\mathrm { C O } _ { 2 }$ 培养箱中培养，隔天用 $0 . 2 5 \\%$ 胰酶消化传代培养。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1.4克隆PTPRCcDNA ",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "根据PTPRC基因序列设计1对基因扩增引物：上游引物5'-CCAAGCTTATGACCATGTATTTGTGGCTTAAAC-3'，下游引物 $5 ^ { \\prime }$ -CCCTCGAGCTATGAACCTTGATTTAAAGCTGGA-3'。上游引物中含有Hind I酶切位点，下游引物中含有XhoI酶切位点，引物由Life公司合成。取健康人外周血，用淋巴细胞分离液分离单个核细胞，提取总RNA，逆转录cDNA后，用高保真DNA多聚酶扩增目的基因。PCR反应体系为 $5 0 ~ \\mu \\mathrm { L }$ 反应条件： $9 5 ~ \\mathrm { ^ { \\circ } C }$ 预变性 $1 \\mathrm { m i n }$ ， $9 5 ~ \\mathrm { ^ { \\circ } C }$ 变性 $2 0 \\mathrm { ~ s ~ } , 5 3 \\mathrm { ~ \\textdegree C }$ 退火 $2 0 \\mathrm { s } , 7 2 \\mathrm { ^ { \\circ } C }$ 延伸 $2 . 5 \\mathrm { m i n }$ ,35个循环；最后 $7 2 \\ \\mathrm { { ^ { \\circ } C } }$ 延伸$5 . 5 \\ \\mathrm { m i n }$ 。回收PCR产物，连接到pMD-18T载体，获得CD45cDNA克隆pMD-18T-CD45。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1.5构建重组表达质粒PcDNA3.1-3xflag-CD45 ",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "采用PCR技术，从质粒pMD-18T-CD45扩增CD45基因片段，分离PCR扩增产物，将其与真核表达质粒PcDNA3.1-3xflag分别用限制性内切酶Hind 和XhoI于 $3 7 ~ \\mathrm { ^ { \\circ } C }$ 双酶切过夜，琼脂糖凝胶电泳回收，取酶切好的PCR产物片段和质粒DNA片段，用T4连接酶于$1 6 ~ \\mathrm { { ^ circ C } }$ 连接 $8 \\mathrm { h }$ ，将连接产物转化感受态Top10菌中，涂在含有 $1 0 0 ~ \\mu \\mathrm { g / m L }$ 氨苄青霉素的LB固体培养基上， $3 7 \\ \\mathrm { { ^ circ C } }$ 培养过夜，次日挑取单克隆菌落，并在含有氨苄青霉素的LB液体培养基摇菌扩增 $^ { 1 4 \\sim 1 6 \\mathrm { ~ h ~ } }$ 。提取质粒PcDNA3.1-3xflag-CD45，送华大基因公司测序。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1.6重组表达质粒PcDNA3.1-3xflag-CD45转染Hela 细胞 ",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "取Hela细胞,加入6孔板内，于 $3 7 \\%$ $\\mathrm { C O } _ { 2 }$ 培养箱培养，次日待细胞贴壁融合生长达孔底面积的 $70 \\%$ ，$80 \\%$ 时，进行细胞转染。DMEM稀释 $2 ~ { \\mu \\mathrm { g } }$ 质粒，加入",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "$2 ~ \\mu \\mathrm { L }$ 转染试剂PEI $\\mathrm { \\Omega } ^ { \\mathrm { 2 } } \\mathrm { m g / m L }$ 混匀，放置 $1 5 ~ \\mathrm { m i n }$ 后，将其缓慢滴入已吸除培养液的6孔板内，置于 $3 7 \\ \\%$ $\\mathrm { C O } _ { 2 }$ 培养箱培养 $4 8 \\mathrm { h }$ ，鉴定CD45的表达及活性。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1.7检测Hela细胞CD45表达",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "用流式细胞术(flowcytometry,FCM)检测CD45表达。细胞转染 $4 8 \\mathrm { ~ h ~ }$ 后，以 $0 . 2 5 \\%$ 胰蛋白酶消化6孔板内细胞，以预冷的含 $1 \\%$ 新生牛血清PBS洗细胞3次，加入PE-CD45抗体， $4 ^ { \\circ } \\mathrm { C }$ 反应 $3 0 \\mathrm { m i n }$ ,用预冷的含 $1 \\%$ 新生牛血清PBS洗3次，上流式细胞仪分析CD45表达情况。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "以免疫印迹(Westernblot,WB)技术分析CD45表达。细胞转染24、48和 $^ { 7 2 \\mathrm { ~ h ~ } }$ 后，提取蛋白，行SDS-PAGE分离，之后将凝胶上蛋白转移到PVDF膜上，用含$5 \\%$ BSA的TBST室温封闭 $2 \\mathrm { ~ h ~ }$ ；加入用TBST1:1000稀释的抗标签抗体， $4 ^ { \\circ } \\mathrm { C }$ 摇床震摇过夜；TBST洗膜3次后，加入HRP-抗鼠抗体，常温下反应 $^ { \\textrm { 1 h } }$ ;TBST洗膜5次后，ECL曝光。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1.8分析CD45酶活性",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "细胞转染后 $4 8 \\mathrm { { h } }$ ，在细胞孔中加入含有蛋白酶抑制剂的裂解液，裂解 $3 0 { \\sim } 4 0 \\ \\mathrm { m i n }$ ,用微量移液器吸出后测蛋白质浓度，严格遵循碱性磷酸酶活性测定试剂盒说明书操作,测定碱性磷酸酶活性，并按说明书公式计算每克蛋白的酶活性。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "1.9统计学方法",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "应用统计学分析软件SPSS16.0(SPSS，Inc.Chicago,IL,USA)进行数据学分析，本研究采用Student's$\\mathbf { \\Phi } _ { t }$ 检验， $P { < } 0 . 0 5$ 认为具有统计学意义。应用软件Graphpadprism5FCSexpression3、Snapgene进行图像处理。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "2结果",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "2.1CD45基因PTPRCcDNA的分离和克隆",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "提取健康人外周血单个核细胞总RNA、逆转录cDNA后，PCR扩增目的基因片段，经 $1 \\%$ 琼脂糖凝胶电泳，可见相对分子质量约 $3 9 0 0 \\mathrm { b p }$ 特异条带(图1),与目的条带CD45大小一致。将其连接到pMD-18T载体，获得CD45cDNA克隆pMD-18T-CD45。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "2.2构建成功CD45真核表达载体",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "将从质粒pMD-18T-CD45扩增出来的PCR产物和空载体PcDNA3.1-3xflag双酶切、连接构建成重组表达载体。该载体约10000bp(图2A带2),以HindI和XhoI进行双酶切鉴定，可见重组质粒在约6000bp和4000bp有特异性条带(图2A带3)。重组表达载体送华大基因测序，测序结果经Blast软件比对，与NCBI公布的序列一致(ID：5788），表明重组真核表达载体PcDNA3.1-3xflag-CD45构建成功(图2B)。",
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "2.3CD45在Hela细胞中表达",
        "text_level": 1,
        "page_idx": 1
    },
    {
        "type": "text",
        "text": "转染重组表达载体PcDNA3.1-3xflag-CD45以及空载体PcDNA3.1-3xflag到Hela细胞48h后，以PE-抗CD45抗体染色，FCM分析可见转染重组质粒的细胞比转染空载体者CD45表达明显增高(图3)。转染24、48、$^ { 7 2 \\mathrm { ~ h ~ } }$ 后进行WB鉴定，在150000(CD45)以及36000(内对照GADPH)处可见特异条带，转染重组质粒的Hela细胞的CD45条带明显深于转染空质粒者，表达在 $^ { 4 8 \\mathrm { ~ h ~ } }$ 达高峰，但 $^ { 7 2 \\mathrm { ~ h ~ } }$ 时仍有表达(图4)。表明PcDNA3.1-3xflag-CD45能有效地转染Hela细胞并表达CD45蛋白。",
        "page_idx": 1
    },
    {
        "type": "image",
        "img_path": "images/0da076b07a4e452de66f028d4a6be00f58a95b832827030e69d0fa417db0e1af.jpg",
        "img_caption": [
            "图1RT-PCR扩增人外周血单个核细胞中CD45 cDNA片段 Fig.1 CD45 cDNA fragment amplified from human peripheral mononuclear cells by RT-PCR.A:DNA maker; B: RT-PCR product; C: Blank control. "
        ],
        "img_footnote": [],
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "2.4Hela细胞表达的CD45具有磷酸酶活性",
        "text_level": 1,
        "page_idx": 2
    },
    {
        "type": "text",
        "text": "提取转染重组表达载体PcDNA3.1-3xflag-CD45或空载体PcDNA3.1-3xflag $^ { 4 8 \\mathrm { ~ h ~ } }$ 后的Hela细胞以及作为阳性对照的天然高表达CD45的人T细胞株Jurkat细胞的蛋白质，分析其磷酸酶活性，发现转染PcDNA3.1-3xflag-CD45的Hela细胞的磷酸酶活性明显高于转染PcDNA3.1-3xflag的细胞( $\\scriptstyle \\left( P < 0 . 0 5 \\right.$ ，图5），表明Hela细胞中表达的重组CD45蛋白具有生物学活性。",
        "page_idx": 2
    },
    {
        "type": "image",
        "img_path": "images/fe5f1bafaf4e7f347211d81875594716dbe4399170e4c9c9a64eea06111f941a.jpg",
        "img_caption": [
            "图2CD45真核表达载体的鉴定"
        ],
        "img_footnote": [],
        "page_idx": 2
    },
    {
        "type": "image",
        "img_path": "images/326d602b4095bbf0816c4b7aaee18c398fd5201ef96ac4575536c4b095478608.jpg",
        "img_caption": [
            "Fig.2 Identification of recombinant expression vector PcDNA3.1-3xflag-CD45. A:Identification of the recombinant expression vector PcDNA3.1-3xflag-CD45 by double restriction enzyme digestion (1:DNA maker; 2:Recombinant plasmid PcDNA3.1-3xflag-CD45;3: Recombinant plasmid after double restriction enzyme digestion ); B:Recombinant plasmid profile. ",
            "图3流式细胞术检测转染质粒后CD45的表达",
            "Fig.3Analysis of CD45 expression in Hela cels transfected with plasmids by flow cytometry.A: Hela cells;B:Hela cels transfected with PcDNA3.1-3xflag;C:Hela cells transfected with PcDNA3.1- 3xflag-CD45. "
        ],
        "img_footnote": [],
        "page_idx": 2
    },
    {
        "type": "image",
        "img_path": "images/e8470c5d515c24816edea50abab916f3e9da0b9696add31fc842d4ed85eeae5e.jpg",
        "img_caption": [
            "图4免疫印迹检测转染质粒后Hela细胞CD45表达情况 Fig.4 Analysis of CD45 expression in Hela cells transfected withPcDNA3.1-3xflag orPcDNA3.1-3xflag-CD45 by Western blotting. "
        ],
        "img_footnote": [],
        "page_idx": 3
    },
    {
        "type": "image",
        "img_path": "images/33dbdc171dbca262aeb3091fc7eff5c86043940d986487ce609f517354fb6a6a.jpg",
        "img_caption": [
            "图5Hela细胞表达重组CD45的磷酸酶活性 Fig.5Phosphatase activityof recombinant CD45 protein expressed in Hela cells. $* * P { < } 0 . 0 5$ "
        ],
        "img_footnote": [],
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "3讨论",
        "text_level": 1,
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "CD45结构分为为胞浆区、跨膜区和膜外区3部分。膜外区包括多态性区域、富含半胱氨酸区域以及保守区域。研究证实，CD45胞外段糖基化种类及程度可调节T细胞的分化、激活、调控和存活[8-10]。文献报道[1],未成熟抗原提呈细胞通过其表面C型凝集素MGL与T细胞表面CD45相互作用，负向调控T细胞的功能;CD45胞浆区结构域具有酪氨酸磷酸酶活性，调控着底物蛋白质的磷酸化，从而调节细胞增殖、分化等。在白细胞中，某些Src酪氨酸激酶家族为CD45的底物，例如,T细胞内Lck和部分Fyn[12],B细胞内Lyn[13],巨噬细胞中的Hck和Lyn[14],以及树突状细胞中的Lyn、Hck和Fyn[15等,其在TCR、BCR、NK细胞以及TLR的信号转导以及白细胞的粘附和迁移中发挥重要作用[1]。因此，在某种意义上,CD45调控着所有白细胞的激活[1。近年来，不仅CD45的调控作用受到关注，其与疾病的关系越来越受到重视，CD45不同亚型的表达与自身免疫病及感染性疾病相关，表明CD45作为重要的免疫调节分子对疾病发生发展有着重要影响[17-19]。同时,CD45抗体靶向造血细胞的免疫治疗受到了越来越多的关注.20]。",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "本研究中，我们将CD45基因从健康人单个核细胞中克隆出来,并将其与表达载体PcDNA3.1-3xflag相连，构建成功重组表达载体PcDNA3.1-3xflag-CD45,转染到Hela细胞中，并能够正确翻译表达。为进一步考察其是否具有生物学活性，我们利用碱性磷酸酶能够分解磷酸苯二钠产生游离酚和磷酸，比色法检测酶活性的原理，发现Hela细胞表达的重组CD45蛋白具有一定的生物学活性。本实验成功地构建了CD45重组表达载体并在Hela细胞中有效表达，建立了有效的进一步研究CD45功能的细胞模型，为进一步揭示CD45的功能及其介导的细胞信号通路奠定了重要的物质基础。",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "随着对CD45分子基因结构和功能的深入认识，CD45在淋巴细胞发育、活化中的作用及其机制等问题的阐明，CD45必将在疾病的诊断、治疗和预后等方面发挥更大的作用。",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "参考文献：",
        "text_level": 1,
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "[1]Saunders AE,Johnson P.Modulation of immune cell signalling by the leukocyte common tyrosine phosphatase,CD45[J].Cell Signal, 2010,22(3): 339-48.   \n[2]Irie-Sasaki J, Sasaki T,Penninger JM.CD45 regulated signaling pathways[J].Curr Top Med Chem,2003,3(7): 783-96.   \n[3]扶云碧,李贵平,孟凡义.90Y标记单克隆抗体CD45的研究[J].南方 医科大学学报,2006,26(8):1230-2.   \n[4]He RJ, Yu ZH, Zhang RY,et al. Protein tyrosine phosphatases as potential therapeutic targets[J].Acta Pharmacol Sin, 2014,35(10): 1227-46.   \n[5］李贵平,郑文莉,黄宝丹,等.CD45 单抗介导的188Re-亲和素二步法 预定位靶向淋巴瘤的实验研究[J].南方医科大学学报,2015,35(8): 1-5.   \n[6]Mawad R,Gooley TA,Rajendran JG,et al. Radiolabeled AntiCD45 antibody with Reduced-Intensity conditioning and allgeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome[J].Biol Blood Marrow Transplant,2014,20(9): 1363-8.   \n[7]Liu T,Cousins A, Chien CC,et al. Immunospecific targeting of CD45 expressing lymphoid cells: towards improved detection agents of the sentinel lymph node[J].Cancer Lett,2013,328(2): 271-7.   \n[8] Clark MC,Baum LG. T cells modulate glycans on CD43 and CD45 during development and activation,signal regulation,and survival [J].Ann NY Acad Sci,2012,1253(1): 58-67.   \n[9]Earl LA,Baum LG. CD45 glycosylation controls T-cell Life and death[J]. Immunol Cell Biol,2008,86(7): 608-15.   \n[10]Xue J,Gao X,Fu C,et al. Regulation of galectin-3-induced apoptosis of Jurkat cells by both O-glycans and N-glycans on CD45 [J].FEBS Lett,2013,587(24): 3986-94.   \n[11] Van Vliet SJ,Gringhuis SI, Geijtenbeek TB,et al. Regulation of effector Tcells by antigen-presenting cells via interaction of the Ctype lectin MGL with CD45[J]. Nat Immunol,2006,7(11): 1200-8.   \n[12]Hurley TR,Hyman R,Sefton BM. Diferential effects of expression of the CD45 tyrosine protein phosphatase on the tyrosine phosphorylation of the lck,fyn,and c-src tyrosine protein kinases［J].Mol Cell Biol, 1993,13(3): 1651-6. ",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "（下转1585页）",
        "page_idx": 3
    },
    {
        "type": "text",
        "text": "（上接1578页）",
        "text_level": 1,
        "page_idx": 4
    },
    {
        "type": "text",
        "text": "[13] Shrivastava P,Katagiri T, Ogimoto M, et al. Dynamic regulation of Src-family kinases by CD45 in B cells[J].Blood,2004,103(4): 1425-32.   \n[14]Roach T,Slater S,Koval M,et al. CD45 regulates Src family member kinase activity associated with macrophage integrinmediated adhesion[J]. Curr Biol,1997,7(6): 408-17.   \n[15]Johnson P, Cross JL.Tyrosine phosphorylation in immune cells: direct and indirect effects on toll-like receptor-induced proinflammatory cytokine production[J].Crit Rev Immunol, 20o9,29(4): 347-67.   \n[16]Buckley RH. The multiple causes of human SCID[J]. JClin Invest, 2004,114(10): 1409-11.   \n[17]Tchilian EZ,Beverley PC.Altered CD45 expression and disease[J] Trends Immunol,2006,27(3):146-53.   \n[18]ChewA,SalamaP,RobbshawA,etal.SPARC,FOXP3,CD8 and CD45correlationwith diseaserecurrenceandlong-term disease-free survival in colorectal cancer[J].PLoS One,2011,6(7): e22047.   \n[19]Colonne CK,Yao JH,Pilgrim C,et al. Surface CD45 expression levels distinguish normal erythroblasts from stress erythroblasts during haemolytic anaemia and pregnancy-induced anaemia [J]. Exp Hematol, 2015,43(9, Supplement): S58.   \n[20]Burtner CR,Chandrasekaran D,Santos EB,et al.(211)AstatineConjugated monoclonal CD45 Antibody-Based nonmyeloablative conditioning for stem cell gene therapy[J].Hum Gene Ther, 2015, 26(6): 399-406. (编辑：经媛） ",
        "page_idx": 4
    },
    {
        "type": "text",
        "text": "",
        "page_idx": 4
    }
]